Anna Axakova

Anna Axakova

Auto-generated profile, based on publicly available information

Anna Axakova

University of Toronto

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 February 2026 in Science
Verified
Journal Article
Closed access
DTDaniel R. Tabet
Daniel R. Tabet
ACAtina G. Coté
Atina G. Coté
MLMegan C. Lancaster
Megan C. Lancaster
JWJochen Weile
Jochen Weile
ARAshyad Rayhan
Ashyad Rayhan
FRFrederick Roth
Frederick Roth
Variants in the familial hypercholesterolemia gene LDLR —the most important genetic driver of cardiovascular disease—can raise circulating low-density lipoprotein (LDL) cholesterol concentrations and increase the risk of premature atherosclerosis. Definitive classifications are lacking for nearly half of clinically encountered LDLR missense variants, limiting interventions that reduce disease burden. We tested the impact of ~17,000 (nearly all possible) LDLR coding variants on both LDLR cell-surface abundance and LDL uptake, yielding sequence–function maps that recapitulate known biochemistry, offer functional insights, and provide evidence for interpreting clinical variants. Functional scores correlated with hyperlipidemia phenotypes in prospective human cohorts and augmented polygenic scores to improve risk inference, highlighting the potential of this resource to accelerate familial hypercholesterolemia diagnosis and improve patient outcomes.

16 September 2025 in The American Journal of Human Genetics
Verified
Journal Article
Open access
AAAnna Axakova
Anna Axakova
MDMegan Ding
Megan Ding
ACAtina G. Cote
Atina G. Cote
RSRadha Subramaniam
Radha Subramaniam
VSVignesh Senguttuvan
Vignesh Senguttuvan
FRFrederick Roth
Frederick Roth
Amyotrophic lateral sclerosis (ALS) is a progressive motor neuron disease for which important subtypes are caused by variation in superoxide dismutase 1 (SOD1). Diagnosis based on SOD1 sequencing can not only be definitive but can also indicate specific therapies available for SOD1-associated ALS (SOD1-ALS). Unfortunately, SOD1-ALS diagnosis is limited by the fact that a substantial fraction (currently 26%) of ClinVar SOD1 missense variants are classified as "variants of uncertain significance" (VUSs). Although functional assays can provide strong evidence for clinical variant interpretation, SOD1 assay validation is challenging given the current incomplete and controversial understanding of SOD1-ALS disease mechanism. Using saturation mutagenesis and multiplexed cell-based assays, we measured the functional impact of over 2,000 SOD1 amino acid substitutions on both enzymatic function and protein abundance. The resulting "missense variant-effect maps" not only reflect prior biochemical knowledge of SOD1 but also provide sequence-structure-function insights. Importantly, our variant-abundance assay can discriminate pathogenic missense variation and provides new evidence for 41% of missense variants that had been previously reported as VUSs, offering the potential to identify additional people who would benefit from therapy approved for SOD1-ALS.

3 July 2026 in bioRxiv
Verified
Preprint
Open access
WLWarren van Loggerenberg
Warren van Loggerenberg
HZHaotian Zhang
Haotian Zhang
VSVignesh Senguttuvan
Vignesh Senguttuvan
MCMichael J Chambers
Michael J Chambers
MPMailoan Panchalingam
Mailoan Panchalingam
FRFrederick P Roth
Frederick P Roth
Hereditary coproporphyria (HCP) — caused by variants in coproporphyrinogen oxidase (CPOX) — can be diagnosed via genome sequencing. However, 74% of clinically-reported CPOX missense variants are classified as variants of uncertain significance (VUS) due to lack of evidence. CPOX variant classification is further complicated by environment-dependence: For example, the CPOX variant p.Asn272His (c.814A>C) is classified as benign yet has been associated with HCP-like symptoms in the context of mercury exposure. Here we measured the functional impact of nearly all possible CPOX amino acid substitutions in both the presence and absence of mercury. The resulting CPOX variant effect maps reflect known protein structure and mutational tolerance patterns while also offering new sequence-structure-function insights. Scores from this atlas not only distinguish pathogenic from benign variants but also identify mercury-dependent variant impacts, thus informing our clinical, structural, and functional understanding of CPOX deficiency and illustrating the value of systematic context-dependent multiplexed assays of genetic variant effects.

28 February 2025 in bioRxiv
Verified
Preprint
Open access
PDF file
AAAnna Axakova
Anna Axakova
MDMegan X Ding
Megan X Ding
ACAtina G. Cote
Atina G. Cote
RSRadha Subramaniam
Radha Subramaniam
VSVignesh Senguttuvan
Vignesh Senguttuvan
FRFrederick Roth
Frederick Roth
Amyotrophic lateral sclerosis (ALS) is a progressive motor neuron disease for which important subtypes are caused by variation in the Superoxide Dismutase 1 gene SOD1 . Diagnosis based on SOD1 sequencing can not only be definitive but also indicate specific therapies available for SOD1 -associated ALS (SOD1-ALS). Unfortunately, SOD1-ALS diagnosis is limited by the fact that a substantial fraction (currently 26%) of ClinVar SOD1 missense variants are classified as “variants of uncertain significance” (VUS). Although functional assays can provide strong evidence for clinical variant interpretation, SOD1 assay validation is challenging, given the current incomplete and controversial understanding of SOD1-ALS disease mechanism. Using saturation mutagenesis and multiplexed cell-based assays, we measured the functional impact of over two thousand SOD1 amino acid substitutions on both enzymatic function and protein abundance. The resulting ‘missense variant effect maps’ not only reflect prior biochemical knowledge of SOD1 but also provide sequence-structure-function insights. Importantly, our variant abundance assay can discriminate pathogenic missense variation and provides new evidence for 41% of missense variants that had been previously reported as VUS, offering the potential to identify additional patients who would benefit from therapy approved for SOD1-ALS.

18 November 2025 in bioRxiv
Verified
Preprint
Open access
AAAnna Axakova
Anna Axakova
ABAmund Holte Berger
Amund Holte Berger
WLWarren van Loggerenberg
Warren van Loggerenberg
NKNishka Kishore
Nishka Kishore
MGMarinella Gebbia
Marinella Gebbia
FRFrederick Roth
Frederick Roth
Pathogenic variants in the Autoimmune Regulator (AIRE) gene cause Autoimmune Polyendocrine Syndrome Type 1 (APS-1), a rare primary immunodeficiency disease with symptoms including hypoparathyroidism, adrenal insufficiency, and chronic mucocutaneous candidiasis. AIRE increases the expression and presentation of tissue-specific genes expressing 'self' antigens in the developing T cell niche, thus triggering the elimination of self-reactive T cells and preventing autoimmunity. Earlier diagnoses can benefit patients, and APS-1 diagnosis by AIRE sequencing is increasingly common. However, two thirds of reported clinical variants are missense, and more than half of these are "variants of uncertain significance" (VUS). Cell-based variant functional assays can provide strong evidence towards more informative variant classification, but these are carried out reactively, often years after clinical presentation. By contrast, proactively assessing all possible missense variants could provide immediate evidence to guide genetic diagnosis, even for never-before-seen variants. Here we used an insulin promoter-driven reporter to proactively assess the function of 9790 AIRE missense variants. The resulting AIRE variant effect map both validates and extends current biochemical knowledge, concords with pathogenicity annotations, and provides proactive evidence for 70% of previously-reported VUS. Placing our map in the context of both an international APS-1 cohort and the UK BioBank revealed quantitative genotype-phenotype correlations. Using current guidelines, we provide classifications for 32% of current VUS. Together, our proactive resource of AIRE variant impacts offers the potential to improve patient outcomes via more rapid and definitive APS-1 diagnosis.